Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2018 | ART: Disappointment with Bilateral Internal-Thoracic Artery Grafts After a 10-Year Follow-Up

Published 5-year results had been neutral for bilateral vs. single internal-thoracic artery grafts, but, at the time, surgeons argued that the time period analyzed was not enough and that a difference would be observed after 10 years of follow-up, once the trial finished. Such follow-up was presented at the European Society of Cardiology (ESC) Congress 2018 and the disappointment was big: bilateral internal-thoracic artery grafts offer no advantage.

ART: desilusión de la revascularización con doble mamaria a 10 años de seguimientoAfter a decade of follow-up, there was no difference between patients who underwent myocardial revascularization surgery involving two bilateral internal-thoracic artery grafts and those with a single arterial graft, plus vein or radial artery grafts, as regards a composite endpoint of death, infarction, and stroke.

 

No differences were observed either as regards major bleeding or repeat revascularization, although patients who received bilateral internal-thoracic artery grafts experienced more infections.

 

The study faced difficulties from the beginning. In fact, 36% of patients received a different strategy than that to which they had originally been randomized. A full 14% of patients randomized to bilateral internal-thoracic artery graft finally received a single internal-thoracic artery graft, while 22% of patients randomized to a single internal-thoracic artery graft received a second arterial graft, generally a radial artery graft.


Read also: ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only.


The use of medical treatment was one of the highlights, ranging from 73% to 89%, following clinical practice guidelines (which include aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers).

 

The primary endpoint, a composite of death, infarction, and stroke, showed no differences between groups (hazard ratio [HR]: 0.90; 95% confidence interval [CI]: 0.78-1.03). Survival curves were nearly juxtaposed throughout the study.


Read also: ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access.


There are several explanations for this disappointment: one might obviously be a lack of difference between these strategies, although there might be other factors involved. High adherence to medical treatment (a novelty, quite higher than rates observed in all other works comparing surgery and angioplasty, for example) may have diluted the expected differences in reintervention. The use of radial artery grafts in the single internal-thoracic artery graft group also may have influenced reinterventions (radial artery grafts proved to be superior to vein grafts), as well as the observed crossover rate, which may have played a part in the results.

 

Original title: Randomized Comparison of Single Versus Bilateral Internal Thoracic Artery Grafts in 3102 CABG Patients: Major Cardiovascular Outcomes at Ten Years of Follow Up.

Presenter: Taggart DP.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...